PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.

Authors :: Borel C
Dastugue N
Cances-Lauwers V
Mozziconacci MJ
Prebet T
Vey N
Pigneux A
Lippert E
Visanica S
Legrand F
Rault JP
Taviaux S
Bastard C
Mugneret F
Collonges Rames MA
Gachard N
Talmant P
Delabesse E
Récher C
Source :: Leukemia research [Leuk Res] 2012 Nov; Vol. 36 (11), pp. 1365-9. Date of Electronic Publication: 2012 Aug 05.
Publication Year :: 2012
Abstract: The PICALM-MLLT10 fusion gene, generated by the t(10;11)(p12-13;q14-21) translocation, is a rare but recurrent event in acute leukemias. In this study, we assessed the characteristics and outcome of 18 PICALM-MLLT10 AML patients. As compared with non PICALM-MLLT10 patients (n=72), PICALM-MLLT10 AML were characterized by more frequent extramedullary diseases, CD7 expression and higher platelet counts. Three out of four therapy-related PICALM-MLLT10 AMLs had been previously treated for diffuse large B-cell lymphoma. The complete response rate was 71% after intensive chemotherapy. PICALM-MLLT10 patients had a shorter median overall survival than patients with favorable cytogenetics (12 months vs. not reached, p=0.07) but not significantly different from those of intermediate (26 months, p=0.32) or unfavorable cytogenetic groups (8 months, p=0.13). Long term responses were achieved in a subset of patients after allogeneic stem-cell transplantation but also after high-dose cytarabine.<br /> (Copyright © 2012 Elsevier Ltd. All rights reserved.)